IDEXX Laboratories, Inc. $IDXX Position Raised by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,739 shares of the company’s stock after acquiring an additional 2,355 shares during the quarter. PNC Financial Services Group Inc.’s holdings in IDEXX Laboratories were worth $25,700,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Elyxium Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $3,666,459,000. State Street Corp grew its position in IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after purchasing an additional 138,956 shares during the last quarter. J. Stern & Co. LLP grew its position in IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of IDEXX Laboratories by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after purchasing an additional 86,263 shares during the period. Finally, Invesco Ltd. increased its stake in shares of IDEXX Laboratories by 13.8% in the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after purchasing an additional 181,955 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.9%

IDEXX Laboratories stock opened at $544.32 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market capitalization of $42.94 billion, a PE ratio of 40.08, a price-to-earnings-growth ratio of 2.95 and a beta of 1.55. The firm has a 50 day simple moving average of $556.27 and a 200-day simple moving average of $595.41.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on IDXX shares. Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.